glp-1 receptor agonists in pediatric and adolescent obesity for the treatment of children adolescents: a meta-analysis of randomized controlled trials Emerging Frontiers in GLP-1 Therapeutics:

Metabolism Ignite and its breakthrough active compound have been tested in 10 published studies

Exendin-4, a glucagon-like peptide 1 receptor agonist, protects against amyloid-beta peptide-induced impairment of spatial learning and memory in rats

doi: 10.1073/pnas.2014879117 [DOI] [PMC free article] [PubMed] [Google Scholar] 98.Frias JP, Hsia S, Eyde S, et al

The 2025 GLP-1 guidelines have positioned these drugs at the forefront of type 2 diabetes management, reflecting their multifaceted benefits

Glucagon-like refers to the fact that the structure of GLP-1 resembles that of glucagon, a hormone involved in regulating blood sugar

Ann Neurol